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Abstract
HIV/HCV coinfected individuals under highly active antiretroviral therapy (HAART) represent an interesting model for the
investigation of the role played by the immune system in driving the evolution of the HCV quasispecies. We prospectively
studied the intra-host evolution of the HCV heterogeneity in 8 coinfected subjects, selected from a cohort of 32 patients
initiating HAART: 5 immunological responders (group A) and 3 immunological non-responders (group B), and in two HCV
singly infected controls not assuming drugs (group C). For all these subjects at least two serial samples obtained at the first
observation (before HAART) and more than 1 year later, underwent clonal sequence analysis of partial E1/E2 sequences,
encompassing the whole HVR1. Evolutionary rates, dated phylogenies and population dynamics were co-estimated by
using a Bayesian Markov Chain Monte Carlo approach, and site specific selection pressures were estimated by maximum
likelihood-based methods. The intra-host evolutionary rates of HCV quasispecies was 10 times higher in subjects treated
with HAART than in controls without immunodeficiency (1.9 and 2.3610
23 sub/site/month in group A and B and 0.29610
23
sub/site/month in group C individuals). The within-host Bayesian Skyline plot analysis showed an exponential growth of the
quasispecies populations in immunological responders, coinciding with a peak in CD4 cell counts. On the contrary,
quasispecies population remained constant in group B and in group C controls. A significant positive selection pressure was
detected in a half of the patients under HAART and in none of the group C controls. Several sites under significant positive
selection were described, mainly included in the HVR1. Our data indicate that different forces, in addition to the selection
pressure, drive an exceptionally fast evolution of HCV during HAART immune restoration. We hypothesize that an important
role is played by the enlargement of the viral replicative space.
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Introduction
Hepatitis C virus is an RNA virus infecting more than 170
million people throughout the world. Like the majority of other
RNA viruses, it is characterised by a high level of genetic
variability that is particularly marked at the level of the E1 and E2
genes encoding viral envelope glycoproteins. The 3’ end of the E2
gene (hypervariable region 1: HVR1) shows frequent mutations
that have the nature of a quasispecies (QS), defined as a population
of closely related but different viral genetic sequences co-existing in
the host and evolving as a single unit [1].
Some authors have suggested that selection pressure due to the
host’s immune response plays a fundamental role in determining
the significant differences in complexity observed in the QS of
patients with different disease outcomes [2–4], but others have not
found any evidence of a correlation between QS complexity and
the humoral immune response, and have suggested that other
factors may provide a better explanation, such as the stage of
infection and the time since its onset [5,6]. Patients with HIV/
HCV coinfection represent a fruitful setting for studying the role
played by the immune response in the heterogeneity of HCV QS
as it is generally accepted that immunosuppression is associated to
a reduced HCV QS complexity [7,8].
Over the last 15 years, the development of highly active
antiretroviral therapy (HAART) has made it possible to restore
immune responses in a large percentage of subjects affected by severe
immunodeficiency due to HIV [9] and, under these conditions, it is
theoretically possible to investigate the effects of the restoration on the
v a r i a b i l i t yo fH C VQ S .H o w e v e r ,t h er e s u l t so fan u m b e ro fs t u d i e so f
the evolution of HCV QS in patients with HCV/HIV coinfection
receiving HAART have been partially conflicting. In particular, some
authors have suggested a correlation between the increase of CD4 cell
counts during therapy and the heterogeneity of HCV quasispecies
population [10–12], but other authors did not observe significant
relationships between HCV heterogeneity and CD4+ cell numbers,
thus suggesting that changes in T-cell functions caused by HAART
may also play a role in conditioning the evolution of HCV QS [13,14].
One of the limitations of these studies is that they were mainly
based on a ‘‘phenetic’’ approach (the statistical evaluation of the
genetic distances and mutant frequency), whereas more sophisti-
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make it possible to estimate the rate of evolution of viral genes and
reconstruct their trees on a real timescale using molecular clock
models based on sequences obtained at different times (heteroch-
ronous sequences) [15].
The application of the coalescent theory [16] to dated
phylogenies has already allowed estimates of viral population
dynamics [17]. This ‘‘phylodynamic’’ approach [18], in combi-
nation with new and more sensitive methods of detecting selection
pressures at individual codon level [19], may better reveal the
evolutionary forces driving the viral heterogeneity in a single host
during the infection, as indicated by recent studies of the intra-
patient evolution of HIV [20,21].
In a preliminary study of 32 patients with HIV/HCV
coinfection enrolled in a HAART protocol, we found that,
although most had very low plasma HCV RNA levels before
treatment, HCV viral load remained unchanged for six months or
more in the majority of immunological non-responders but
increased in a large proportion of the patients whose CD4+ cell
counts significantly increased more than 1.5-fold during treatment.
In order to investigate the forces acting on the evolution of HCV
QS during HAART and clarify the effect of a restored immune
response on viral diversification, we studied the within-host
dynamics of the QS populations in a subgroup of these showing
an immunological response to HAART or not. QS heterogeneity
was characterised before and after at least one year of HAART,
and its molecular evolution and population dynamics was studied
phylogenetically and compared with those of two HIV-negative
and drug naı ¨ve subjects.
Methods
Ethics Statement
The authors were exempted from prior approval by the IRB of
Luigi Sacco Hospital, Milan, Italy. The analyses were conducted
on stored serum samples collected anonymously and identified
through an internal code. Individuals’ clinical and demographic
data, were recorded anonymously in a database. The informed
oral consent obtained from our patients was registered in each
chart, which at that time was in paper format. The study was
conducted in accordance with the 1964 Declaration of Helsinki
and the ethical standards of the Italian Ministry of Health.
Patients and samples
The study patients were retrospectively selected from a cohort of
32 patients with HIV/HCV coinfection entered in a HAART
protocol whose main demographic, immunological, virological
and clinical data were stored in a database (see Table 1). The
stored data included the findings of laboratory analyses (such as
CD4+, CD8+ and CD19+ cell counts, serum ALT levels, HCV
viremia and genotype) of all patients. Serum samples collected
before and at least six months after the start of HAART, were
stored under optimal conditions at 280uC. None of the patients
were receiving any antiviral therapy at the time of enrolment and
they were all serum HBsAg negative. At the end of the follow-up
(mean 30.469.2 months), CD4+ cell counts had increased more
than 1.5 times from baseline in 20 immunological responders
(62.6%; group A), and decreased or increased less than 1.5 times in
12 immunological non-responders (37.5%; group B).
A preliminary analysis of these 32 patients showed that all of
them had a low plasma HCV RNA load at the time of enrolment
(mean limiting dilution titre: log 1.5961.4 PUs-see Methods for
details) but, by the end of the follow-up, this had significantly
increased (p,0.001 by Wilcoxon’s test) only in group A patients.
As we were interested in studying the intra-host evolution of HCV
QS, we further analysed all of the patients with at least one HCV
RNA-positive sample before HAART (T0) and one collected after
at least one year on HAART (T1): five immunological-responders
(group A) and three immunological non-responders (group B)
having demographic and laboratory characteristics not signifi-
cantly different from those of the population as whole, met this
criterion (Table 2). In addition, we also included two HIV-1
seronegative patients with community-acquired chronic type C
hepatitis who had been followed up for more than 48 months
(group C).
Table 1. Demographic and clinical characteristics of the 32 HIV/HCV coinfected patients by immunological response to HAART.
Characteristics Immunological Responders Non-responders
N. (%) 20 (62.5%) 12 (37.5%)
Mean age (years) 49.8 48.9
Male:female 15:5 9:3
Mean CD4 baseline (6SD) 106.9 (110.1) 194.9 (152.3)
Mean CD4 end* (6SD) 376.3 (213.7) 257.7 (178.2)
Mean CD8 baseline (6SD) 821.3 (733.4) 854.9 (431.1)
Mean CD8 end (6SD) 1255.6 (686.0) 1003.4 (341.8)
Mean CD19 baseline (6SD) 216.8 (314.2) 139.0 (151.4)
Mean CD19 end (6SD) 628.6 (397.4) 501.7 (168.2)
Genotype 1 N. (%) 8 (61.5%) 3 (42.9%)
Genotype 3 N.(%) 4 (30.8%) 3 (42.9%)
Genotype 4 N. (%) 1 (7.7%) 1 (14.3)
HCV viremia baseline (6SD) 1.59 (1.4) 1.9 (1.4)
HCV viremia end (6SD) 2.25 (1.2) 1.7 (1.2)
*end of follow-up.
CD4, CD8, CD19 cell counts are expressed in cells/ml.
N.: number.
doi:10.1371/journal.pone.0016551.t001
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Total RNA was extracted from 200 ml of plasma using a
commercially available kit based on affinity column purification
(High-Pure Viral RNA Kit, Roche Diagnostics, Mannheim,
Germany). HCV RNA was detected by means of reverse
transcription (RT) nested-PCR for the amplification of the 59
non-coding region (NCR) sequences, and its plasma levels were
measured by means of limiting dilution PCR, as described
elsewhere [22], which was the reference method for plasma
HCV-RNA quantitation at the time of study initiation. The HCV
RNA titres were expressed as the highest dilution giving a positive
result in 1 ml of plasma (PCR units [PUs]). The HCV quasispecies
were molecularly characterised by amplifying a 351-nucleotide
sequence encompassing the E1/E2 region (including HVR1). RT
nested-PCR was performed using two pairs of primers recognising
the main HCV genotypes circulating in Italy: outer primers 59-
GGDCAYCGMATGGCNTGGGA-39 (positions 1284-1303) and
59-GGNGSRTARTGCCAGCARTANGG-39 (positions 1813-
1791), and inner primers 59-GCTTGGGATATGATGAT-
GAACTGGTC-39 (positions 1296-1321) and 59GGTGTGGA-
GGGAGTCATTGCAGTT39 (positions 1646-1623). The se-
quences encompassing the E1/E2 were inserted in the plasmid
vector pGEM (pGEM-T Easy Vector System II, Promega Corp.,
Madison, WI) and transfected into competent Escherichia coli
JM109 cells. After overnight incubation at 37uC in agar medium,
the insertion was checked by means of PCR using HCV envelope
inner primers on white colonies. A total of 260 HCV-positive
clones from each sample were then bi-directionally analysed by
means of automated sequencing (ABI Prism 3100 Genetic
Analyzer, Applied Biosystems Division, Foster City, CA) in the
presence of the specific inner primers described above, and the
ABI Prism BigDye terminator cycle sequencing ready reaction kit
(Applied Biosystems).
Each sample was phylogenetically analysed using a 261-
nucleotide sequence included in the E1/E2 genes and encom-
passing HVR1 (nucleotides 1491-1571). The sequences have been
submitted to GenBank (accession numbers to be given).
Phylogenetic analysis
For the purposes of subtyping, the patients’ sequences were
aligned with nine HCV reference sequences retrieved from the
GenBank database (accession numbers in brackets): HCV1a
(M62321); HCV1b (D10074); HCV2a (D00944); HCV2b
(D10988); HCV2c (1:AF142392; 2:D31972); HCV2e/f
(D49757); HCV3a (D14311); and HCV4a (Y11604) [23].
Ten different sequence datasets (each containing all of the
isolates obtained from every patient or control at different time
points) were aligned using the CLUSTALW program [24], and
the best fitting nucleotide substitution model was tested by means
of a hierarchical likelihood ratio test (LRT) implemented in
Modeltest 3.07 software [25]. The calculations were made using
PAUP* software version 4.0 (D. L. Swofford, Sinauer Associates,
Inc., Sunderland, MA). The selected model was HKY [26], which
showed gamma-distributed rates among sites for all datasets.
Distance matrices were calculated using Molecular Evolutionary
Genetics Analysis (MEGA) vs. 4 software [27], and were expressed
as substitutions per 100 sites. Synonymous (dS) and non-
synonymous (dN) distances were estimated for the HVR1
sequences under the Nei and Gojobori model [27] with the
Jukas-Cantor correction.
An unrooted phylogenetic tree was obtained for every patient
using a Bayesian approach implemented in the MrBayes program
[28].
Evolutionary rate estimation and demographic analysis
Dated trees, evolutionary rates and population growth models
were co-estimated using a Bayesian Markov Chain Monte Carlo
(MCMC) method implemented in the BEAST package [15]
(available at http://beast.bio.ed.ac.uk/).
Evolutionary rates were estimated using both a strict and
relaxed molecular clock. As coalescent priors, we compared three
parametric demographic models of population growth (constant
size, exponential, and logistic growth) and a non-parametric,
piecewise-constant Bayesian skyline plot (BSP). The best fitting
models were selected by means of a Bayes factor (marginal
likelihood) implemented in BEAST [29]. In accordance with Kass
and Raftery (1995), the strength of the evidence against H0 was
evaluated as 2lnBF,2: no evidence; 2–5: weak evidence; 6–10:
strong evidence; and .10: very strong evidence. A negative
2LnBF indicates evidence in favour of H0. Only values of $10
were considered significant. When the posterior distribution of the
growth rate contained a zero value in the 95% highest posterior
density (95% HPD), we did not reject the constant population in
favour of the exponential growth model.
Table 2. Demographic and clinical characteristics of the HIV-1/HCV coinfected patients under HAART in group A (Pat# 1-5) and
group B (Pat# 6-8).
Pat# Gender Genotype
HCV
viremia ALT CD4 CD8
ARV before
HAART
T0 T1 T0 T1 T0 T1 T0 T1
1 M 1 1 1 43 350 40 179 698 874 2
2 M 1 1 1 63 210 29 176 554 771 0
3 M 3 2 3 54 56 97 261 411 851 4
4 F 1 1 3 362 310 260 413 611 340 2
5 M 1 3 3 74 48 105 630 2258 1461 3
6 F 3 1 3 117 310 145 189 762 709 5
7 M 1 3 3 217 327 217 305 1365 998 6
8 M 1 3 3 40 42 290 266 1455 756 1
Units used. Age:years; ALT levels: units/L; Cell counts: cells/ml; HCV viremia: log of the limiting dilution titer; ARV before HAART: years.
Pat#: Patient number.
doi:10.1371/journal.pone.0016551.t002
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sampled every 2000–3000 steps. Convergence was assessed on the
basis of the effective sampling size (ESS) after a 10% burn-in using
Tracer software version 1.3 (http://tree.bio.ed.ac.uk/software/
tracer/). Only ESS’s of .250 were accepted. Uncertainty in the
estimates was indicated by 95% HPD intervals. The trees were
summarised in a maximum clade credibility tree using the Tree
Annotator program included in BEAST by choosing the tree with
the maximum product of posterior probabilities after a 10% burn-
in; this tree was then visualised using the program FigTree 1.2
(available at http://tree.bio.ed.ac.uk/software/figtree/).
Selection pressure analysis
The dN/dS rate (v) was estimated using the Maximum
Likelihood (ML) approach implemented in the HyPhy software
[30]. In particular, the global model (which assumes a single
selective pressure for all branches) was compared with the local
model (which allows selective pressure to change along every
branch) using the likelihood ratio test (LRT): the second model
was not better than the first in any of the patients.
Site-specific positive and negative selections were estimated
using three different algorithms: single likelihood ancestor
counting (SLAC), derived from the Suzuki-Gojobori approach
[31]; fixed-effects likelihood (FEL), which fits an v rate to every
site and uses the likelihood ratio to test whether dN ?dS; and
random effect likelihood (REL), a variant of the Nielsen-Yang
approach [32] that assumes the existence of a discrete distribution
of rates across sites, and allows both dS and dN to vary
independently site-by-site. The three methods have been described
in more detail elsewhere [19]. In order to select the sites under
selective pressure, we assumed a p value of #0.1 or a posterior
probability of $0.9 [19]. The Hyphy software was used for all of
the analyses, some of which were made using the Web-based
Datamonkey interface (http://www.datamonkey.org/) [30].
The presence of recombination events was investigated using
GARD [33], a genetic algorithm implemented in Datamonkey to
identify non-recombinant fragments; recombinant sequences were
excluded from the subsequent analyses.
Results
Characteristics of the study population
The immunological responders (group A) were followed up for a
mean of 26611.1 months; the immunological non-responders
(group B) for a mean of 2367.5, and the group C controls for a
mean of 65624 months. There were no significant differences in
mean peripheral blood cell counts between group A and B at
baseline; during follow-up, there were statistically significant
increases in the mean CD4+ cell counts (from mean 106 to 332
cells/ml-p=0.04, matched pair t test) in group A but not in group
B patients (Table 2). The curves on Figure 1 illustrate the changes
in CD4 positive cells during the follow-up for each coinfected
patient.
QS heterogeneity
The phylogenetic analysis was based on a 261-nucleotide
sequence included in the E1/E2 genes and encompassing HVR1.
A total of 260 sequences were analysed: a mean of 11.8 (10-20)
clones per patient and per timepoint.
Table 3 shows mean intra-patient mutant frequencies, genetic
distances, and synonymous (dS) and non-synonymous (dN)
substitution rates. At T0, there were no significant differences in
any of these parameters in the whole E1/E2 sequences or HVR1
alone between group A and B (p values between 0.2 and 1 by
Kruskal Wallis test), whereas the subjects in group C tended to
have higher mean mutant frequencies and mean genetic distances
than the HIV1-positive patients in both sequences, although the
differences were not significant (p$0.07, Kruskal Wallis test).
During the follow-up, the mean mutant frequencies and genetic
distances in the E1/E2 region at T0 and T1 increased significantly
in group A (p=0.04, Wilcoxon’s test), but were non-significantly
different in group B (p$0.28, Wilcoxon’s test) and group C
(p=0.6, Wilcoxon’s test) patients. These findings were confirmed
when the analysis was limited to HVR1. In particular, the
calculation of dS and dN showed a statistically significant (p=0.04-
by Wilcoxon’s test) increase in non-synonymous and an almost
significant (p=0.07) increase in synonymous substitution rates in
group A, but no changes (p$0.1) in group B or group C (Table 3).
No correlation between QS heterogeneity parameters and the
infecting genotype has been evidenced [data not shown].
Bayesian phylogenetic analysis of HCV QS at T0 and T1
Analysis of the Bayesian maximum credibility trees showed that
pre- and post-HAART QS segregated into separate well-
supported (posterior probability.0.8) monophyletic groups in
seven of the eight patients with HIV-1/HCV coinfection; in one
group B subject (#7), several clones isolated at different times
appeared intermixed, not segregating into significant clades. The
patients for whom tree samples were available showed subsequent
replacements of the main viral QS by new variants at all
timepoints. In group C, the T0 and T1 clones were included in
separate clades in one subject (#9) and were partially intermixed
in the other (#10). Trees in Figure 2 represent the Bayesian
phylogenies of HCV QS at different times during the follow up in
four typical subjects: two group A (subjects #5 and #4), one group
B (subject # 7) and one group C (subject#9) individual. The other
trees are reported on the supporting figure 1 (Figure S1).
Estimated evolutionary rates and tMRCAs
Comparison of the strict and relaxed molecular clock models
showed that the first fitted the data better than the second in all
subjects. In the strict clock model, the evolutionary rate estimates
were similar in group A and B (median values respectively 1.9 and
2.3610
23 sub/site/month); the estimate was significantly lower
than in all of the other coinfected subjects in one group B subject
(#7 again): 0.17610
23 sub/site/month (95%HPD 0.03-
0.3610
23) (Table 4). There were no differences between the
relative evolutionary rates at codon positions 1
st+2
nd (mainly
associated with non-synonymous mutations) and those at codon
position 3
rd (frequently synonymous). However, the median
evolutionary rate in the two HIV-negative subjects with chronic
HCV infection was 10 times lower than that in the HAART-
treated subjects (0.29610
23 sub/site/month), and the relative
evolutionary rate at codon positions 1
st+2
nd was between 1.4 and
5.5 times lower than that at codon position 3
rd (Table 4).
The tMRCA estimates of the root for each dated tree showed
that it was no more than 12 months before T0 in all but two of the
HAART-treated subjects, but preceded T0 by more than 36
months in one group A patient (#3), one group B patient (#7),
and both group C patients.
Demographic analysis
Comparison of the different coalescent models (constant
population size, exponential growth and BSP) showed that the
BSP fitted the data better than the other models in nine out of ten
patients (Table S1); the exponential population growth model was
selected (2lnBF=37.6) in one group A patient (#3).
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increase in the size of the QS population in all the group A
subjects, which started immediately after the initiation of HAART
(in patients #5 and #1), or later (in patients #4 and #2) but
always chronologically coinciding with a significant increase in
CD4 cell counts; on the contrary, the size of the QS populations in
the subjects in groups B and C remained constant during the
follow-up. The curves illustrating the changes in the effective HCV
QS population size during time for four exemplary subjects (two
group A one group B and one group C, the same of figure 2), are
reported on Figure 3. The remaining BSPs are reported in
supporting figure 2 (Figure S2).
It was possible to estimate exponential growth rates in three
group A patients using parametric models, which showed values of
between 0.060 and 0.191 months
21, corresponding to a
duplication time of between 11.5 and 3.6 months.
Site-specific selection pressure
Comparison of the different evolutionary models allowing site-
specific dN/dS rates (Niels-Yang and REL) showed that positive
selection pressure was significant in three group A, one group B,
and neither of the group C subjects (Table 5). Using different
approaches and considering only the results supported by two or
more methods, we found that 18 of the 87 analysed E1/E2 sites
(20.6%) were under positive selection pressure, 14 of which
(77.8%) were included in HVR1. Five sites (384, 396, 397, 399
and 417) also showed positive selection in internal branches
(indicated by asterisks in Table 5). Amino acids modifications
observed in the positively selected sites are reported in detail in
Table S2.
Sites under significant negative selection were found by REL
and FEL in three group A, all group B and both group C subjects.
Twenty-four of the 87 codons in E1/E2 (27.6%) were under
purifying selection pressure, eight of which (33.3%) were included
in HVR1. Twelve of the 24 sites also showed significant negative
selection in internal branches (Table 5).
The most frequently positively selected codons were 384, 397
and 401 (which were under significant positive selection pressure
in three out of four subjects), followed by sites 396 and 399, which
were positive in two out of four subjects. The most represented
E1/E2 codons under negative selection pressure were present in
only two out of eight subjects (sites 339, 355, 361, 378 and 409); all
of the other sites were only detected in one patient at a time
(Figure 4).
Figure 1. Changes in CD4 cell counts during HAART treatment of 5 group A and 3 group B HIV/HCV coinfected patients. Curves
represent the absolute number of CD4 cells/ml of peripheral blood (y axis) over time (x axis-months before the most recent sample) for each HAART
treated patient. Subjects#1-5: immunological responders (group A); subjects#6-8 non responders (group B). The vertical yellow line indicates time of
HAART initiation.
doi:10.1371/journal.pone.0016551.g001
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Early studies of the impact of HAART on liver disease in
patients with HIV/HCV coinfection generally suggested its
beneficial effect on the progression of fibrosis [34,35], but an
uncommon increase in transaminase levels accompanied by higher
HCV viremia levels was also reported [36,37]. During a
preliminary follow-up of 32 patients with HCV/HIV coinfection
entering a HAART protocol, we found that serum HCV RNA
levels increased in a significant proportion of immunological
responders.
Genetic distance analysis (phenetic approach) of the QS
obtained before the patients started HAART and after more than
one year of treatment showed that mutant frequency and mean
genetic distance both significantly increased in immunogical
responders, and there was a significant increase in both
synonymous and non-synonymous substitution rates at the level
of HVR1. On the contrary, no significant changes in QS
heterogeneity parameters were observed in the group C controls.
A number of authors have previously studied the evolution of
HCV QS in coinfection subjects during HAART. Although their
findings are partially conflicting, the majority agree on two
observations: a relatively low level of HCV heterogeneity before
HAART, but an increase in QS complexity and dN/dS ratios after
prolonged treatment [10–12,14,38].
Our own analysis of dated trees showed that the clones isolated
at different times in each patient were always clearly monophy-
letic, except in the case of one patient in group B (#7) and one in
group C (#9) whose sequences isolated at T0 and T1 showed a
degree of intermixing. In the majority of the HAART-treated
patients, the estimated tMRCA of the tree root (which represents
the time at which the sampled viral variants shared the same
ancestor) [39], was within 12 months before treatment initiation,
whereas it was placed years before T0 in both of the group C
controls. Our patients had very probably been infected with HCV
for several months or years before starting HAART, which
suggests that the clones analysed in the majority came from the
expansion during HAART of a few viral variants existing at T0.
Analysis of the internal node tMRCAs showed that the most
heterogeneous QS population in the immunological responders
emerged during a period of time in which there was a documented
increase in CD4+ cell counts. This suggests that, during HAART
(and particularly at the time of an increase in CD4+ cell counts), a
more heterogeneous and rapidly evolving QS population arises
within the host that diverges from and predominates over the few
pre-existing variants.
Interestingly, we estimated very rapid within-host evolutionary
rates during HAART, regardless of the immunological response to
therapy: the median values in group A and B were respectively 1.9
and 2.3610
23 sub/site/month (corresponding to 2.2 and
2.7610
22 sub/site/year), significantly higher than that calculated
in group C (2.9610
24 sub/site/month, corresponding to
3.5610
23 sub/site/year). Only group B patient #7 showed a
low intra-host evolutionary rate similar to that in the group C
controls. Previous studies have reported various estimates of the
evolutionary rate of E1/E2 and HVR1 in HCV-infected patients
[5,7,40-46]. Considering only the most recent, these vary from
0.1610
23 to 6.6610
23 sub/site/month, a range that includes the
values obtained in our group C subjects, but not the higher values
observed in our HAART-treated subjects.
Moreover, the substitution rate at codon position 3
rd (which less
frequently causes amino acid changes) in the group C controls was
significantly higher than that estimated at codon positions 1
st+2
nd
(which always causes amino acid changes), whereas there were no
differences between the relative evolutionary rates estimated at the
different codon positions in any of the HAART-treated patients.
This is in line with the increase in both non-synonymous and
synonymous substitution rates found in our phenetic analysis. It is
well known that synonymous substitutions are selectively neutral in
the majority of cases, and we can hypothesise their increased rate
was due to more rapid HCV replication and shorter generation
times after the start of HAART. This hypothesis is supported by
the phylodynamic analysis showing that the HCV QS populations
exponentially grew during follow-up in the immunological
responders, but remained constant over time in the immunological
non-responders and controls. In particular, the growth in the QS
Table 3. Mean mutant frequency, mean genetic distance and dS and dN (x100 sites) of the HCV plasma quasispecies in 10 patients
included in the analysis at different times.
E1/E2 HVR-1
Group Time M.f. (±SD) G. d (±SD) M.f. (±SD) G. d (±SD) dS (±SD) dN (±SD)
A T0 0.27 (0.1) 0.4 (0.3) 0.18 (0.06) 0.86 (0.7) 0.7 (1.0) 0.44 (0.3)
T1 0.79 (0.09) 3.1 (2.7) 0.6 (0.2) 8.1 (8.5) 4.5 (3.4) 7.4 (3.4)
p
a 0.04 0.04 0.04 0.04 0.04 0.07
B T0 0.36 (0.26) 0.7 (0.5) 0.32 (0.14) 0.87 (0.6) 1.4 (1.0) 0.2 (0.2)
T1 0.40 (0.26) 1.8 (2.1) 0.27 (0.12) 5.9 (7.2) 0.8 (0.9) 2.3 (0.6)
p
a 0.593 0.285 1.0 0.1 0.1 0.6
C T0 0.6 3.6 0.4 5.6 5.8 5.5
T1 0.6 4.1 0.5 3.3 6.0 2.1
p
a 1.0 0.6 0.6 0.6 0.6 0.6
M.f.=mutant frequency (mutant clones/total clones).
G.d=Genetic distance.
dS/dN= synonymous/non-synonymous substitutions.
SD= standard deviation.
T0 = Baseline.
T1 = Post-treatment: the latest post treatment values.
p
a = level of significance comparing T0 and T1 by Wilcoxon’s test.
doi:10.1371/journal.pone.0016551.t003
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the responders.
Other stochastic factors, such as a bottleneck effect due to
significant changes in the size of a viral population can
indifferently influence the rates of synonymous and non-synony-
mous substitutions. In our preliminary study, we found that the
HCV viral loads were very low at baseline but increased rapidly in
a significant proportion of the immunological responders. Taken
together, the above data indicate that an increase in the replication
activity of HCV causes an expansion of the QS population in
immunological responders during HAART.
One possible reason for this increase in viral replication is
positive selection pressure due to the restored immune response
in HAART-treated patients. The 27 amino acid N-terminal of
glycoprotein E2 forming the basic ectodomain HVR1 probably is
not part of a folded domain and includes epitopes that are
targeted by neutralising antibodies [47,48], which explains why
its variability may represent an immune system escape strategy
[47,49]. We found significant positive selection acting on the QS
of three immunological responders and one non-responder, but
not on those of either of the group C controls. As previously
described by a number of research groups and our own [23,50],
the majority of the sites under positive selection pressure (78%)
were localised in the HVR1, and three of them (384, 397 and
396) were also under significant positive pressure at the level of
internal branches, which ignore the possibly deleterious muta-
tions frequently found in terminal branches. No fixation of
specific mutations has been observed, thus suggesting a
diversifying selection mechanism, aimed to maintain high level
of amino acid diversity at codon positions under host immune-
response [51].
E1/E2 glycoproteins play key roles in the life cycle of HCV
[52]. They are also essential for modulating virus entry [53], and it
has been shown that HVR1 is essential for binding the virus to the
co-receptor human scavenger receptor class B type I [54–56]. For
these reasons, despite the frequent site mutations due to immune
escape, envelope glycoproteins and HVR1 contain several highly
conserved codons. The majority of the patients analysed in our
Figure 2. Bayesian phylogenetic trees of the HCV E1/E2 sequences at different times during follow-up. Four exemplary trees obtained
from two immunological responders to HAART: subject #5 (A); subject #4 (B), one non-responder: subject #7 (C), and one patient not receiving
HAART: subject #9 (D). The clones isolated in the basal, intermediate and/or last samples are indicated by black circles, blue triangles and red
squares, respectively. The other trees are shown in Supporting Figure 1 (Figure S1). The branches are shown in units of time, and the numbers on the
branches indicate posterior probabilities. Asterisks indicate significant branches (pp.0.65). The months before the last sample are shown in the scale
at the bottom of the trees. The vertical line indicates time of HAART initiation (orange line) or T0 (black line).
doi:10.1371/journal.pone.0016551.g002
Within-Host Dynamics of HCV Quasispecies
PLoS ONE | www.plosone.org 7 January 2011 | Volume 6 | Issue 1 | e16551Table 4. Mean evolutionary rate estimates (x10
23) and 95%HPD for whole E1/E2 sequences and separate codon positions (1
st +2
nd
and 3
rd) and root tMRCAs (in months before the last sample) and months of follow-up in 8 patients and 2 controls.
Patient M.E.R. (95%HPD) R.E.R.1
st+2
nd (95%HPD) R.E.R. 3
rd (95%HPD) R.tMRCA (95%HPD) Months
# 1 1.9 (1.1–2.9) 0.9 (0.7–1.2) 1.1 (0.6–1.6) 36.9 (36–38) 36
# 2 0.6 (0.2–1.1) 0.9 (0.6–1.2) 1.2 (0.6–1.8) 37.2 (27–53) 26
# 3 2.0 (0.4–3.4) 1 (0.7–1.3) 1.0 (0.5–1.5) 33.3 (20–70) 24
# 4 1.0 (0.5–1.6) 0.8 (0.5–1.1) 1.4 (0.9–2.0) 43.7 (39–50) 39
# 5 2.1 (1.3–2.9) 1.1 (0.8–1.3) 0.9 (0.5–1.3) 33.6 (33–34) 33
# 6 2.8 (1.7–4.2) 1 (0.8–1.2) 0.99 (0.6–1.4) 22.9 (21–25) 20
# 7 0.17 (0.03–0.3) 1.1 (0.7–1.3) 0.9 (0.3–1.5) 78.0 (35–144) 30
# 8 2.3 (0.9–3.7) 1.2 (0.9–1.5) 0.6 (0.1–1.6) 14.5 (14–15) 14
# 9 0.37 (0.15–0.6) 0.4 (0.2–0.6) 2.2 (1.8–2.6) 76.8 (52–119) 48
# 10 0.22 (0.06–0.4) 0.9 (0.6–1.1) 1.3 (0.7–1.9) 295.9 (137–525) 82
Group A: Subjects #1-5; group B: Subjects #6-8; group C (controls): Subjects #9 and 10.
E.R.=Evolutionary rate estimates in substitution/site/year.
R.tMRCA= Tree root time (months before the most recent sample).
M.E.R.= Mean evolutionary rate.
R.E.R.=Relative evolutionary rate.
doi:10.1371/journal.pone.0016551.t004
Figure 3. Intra-host population dynamics of the HCV QS during follow-up. Bayesian skyline plots of the effective HCV population size (y
axis) over time (months before the last sample; x axis) in four representative subjects (the same of Figure 1), two immunological responders: subject
#5 (A) and subject #4 (B), one non-responder: subject #7 (C), and one patient not receiving HAART: subject #9 (D). The graphs represent the
median estimate (black line) of the effective population number of HCV (the number of infectious genomes effectively contributing to the next
generation) with shaded area representing the 95% high posterior intervals. The vertical line corresponds to the time of HAART initiation (red) or T0
(black), and the dotted line corresponds to the lower 95% HPD limit of the root tMRCA. The other BSPs are shown in Supporting Figure 2 (Figure S2).
doi:10.1371/journal.pone.0016551.g003
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that were widely distributed along the envelope glycoproteins.
The main limitations of our study are the small number of
patients included and the relatively low mean number of clones
(11.8) analysed for each sample. Nevertheless it has been
previously shown that the statistical power of genealogy is
optimized by sampling even a modest number of variants from a
larger population [57].
In brief, our data suggest that HCV QS undergo exceptionally
rapid evolution in HAART-treated patients with HIV/HCV
coinfection, and that this is associated with an increase in QS
heterogeneity in immunological responders. This seems to be due
Table 5. Significance level (p value) of the positive selection versus neutral model comparison by two different methods (NY, REL
see methods section for details) and sites under positive or negative selection.
Patient NY REL Positive selection Negative selection
# 1 ,0.001 ,0.001 401, 405 341, 378*
# 2n s n s- -
# 3 ns 0.002 372, 384, 397, 399, 401 340, 344, 354*, 370, 411
# 4 0.1 0.04 417* -
# 5 ,0.001 ,0.001 365, 384*, 392, 396, 397*, 400, 403, 410 346*, 359*, 383
# 6 ,0.01 0.001 349, 384, 386, 396*, 397, 398, 399*, 401, 408, 410 339*, 355*, 363*, 365
# 7 ns ns - 398
# 8 ns ns - 409*
# 9 ns ns - 339*, 341, 361, 384, 394, 399*, 403
# 10 ns 0.02 - 342*, 355*, 361*, 378*, 397*
n.s.= not significant (p.0.1).
*=indicates sites under significant selection at internal branches.
doi:10.1371/journal.pone.0016551.t005
Figure 4. Frequency and distribution of the sites under significant positive and negative selection pressure inE1/E2. The bars indicate
the number of patients (y axis) showing positive (filed bars-upward) or negative (striped bars-downward) selection at each site (x axis).
doi:10.1371/journal.pone.0016551.g004
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also suggested by the findings of our preliminary study showing a
significant increase in viral load among immunological responders.
Interestingly, in the same subjects, the QS population underwent
expansion at the same time as CD4+ cell counts increased, which
suggests that the increase in the HCV replication is due to an
adaptive response to the recovery of host immucompetence.
Nevertheless, we found significant positive selection pressure in
only half of our HAART-treated patients.
Another possible cause of the enhancement of viral replication
(and a prerequisite for the development of new viral variants with
greater fitness) is the supply of new uninfected cells susceptible to
HCV infection causing an enlargement in viral replication space.
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last samples are indicated by black circles, blue triangles and/or
red squares, respectively. The branches are shown in units of time,
and the numbers on the branches indicate posterior probabilities.
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